About Cyxone

Cyxone develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. Our goal is to improve the quality of life for patients in need of a more effective, convenient and safe treatment option.

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Our mission is to provide better therapies for patients suffering from autoimmune diseases

Press Releases

Cyxone AB carries out a rights issue of shares of approximately MSEK 36.3

September 25, 2023 19:40 (CEST)

Regulatory
Interim Report 1 January to 30 June 2023

August 30, 2023 08:32 (CEST)

Regulatory
Cyxone revises strategy for commercial alignment targeting valuable market opportunities

August 29, 2023 19:03 (CEST)

Regulatory

About Cyxone

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

Multiple sclerosis (T20K)

Press Releases

Cyxone AB carries out a rights issue of shares of approximately MSEK 36.3

Interim Report 1 January to 30 June 2023

Cyxone revises strategy for commercial alignment targeting valuable market opportunities

Subscribe to Press Releases